PURPOSE: To report the long-term outcomes of penetrating keratoplasty (PKP) in war victims with chronic and delayed mustard gas keratitis. METHODS: This noncomparative interventional case series includes patients with advanced chronic or delayed mustard gas keratitis who had undergone PKP from 1989 to 2006. Best-corrected visual acuity (BCVA), graft clarity, episodes of graft rejection, duration of steroid use, and complications were evaluated. Histopathologic features of excised corneal buttons were also evaluated. RESULTS: Overall, 22 eyes of 19 patients underwent PKP. Mean age at the time of surgery was 41 +/- 4.6 years (range, 36-54 years), and mean follow-up duration was 40.9 +/- 48 months (range, 4-204 months). The graft remained clear in 17 (77.3%) eyes and failed in 5 (22.7%) eyes. Overall, 13 (59.1%) eyes experienced episodes of endothelial rejection, and 5 (22.7%) eyes had subepithelial immune rejection, 4 of which had simultaneous endothelial rejection. Fifteen (68.2%) eyes received topical steroids for >6 months. Fourteen (63.6%) eyes developed cataracts, leading to cataract extraction in 7 eyes. One eye developed steroid-induced glaucoma after multiple episodes of endothelial graft rejections. Mean preoperative BCVA was 1.92 +/- 0.63 logMAR, which improved to 1.04 +/- 0.65 logMAR (20/200) overall and 0.8 +/- 0.3 logMAR (20/120) in eyes with clear grafts (P < 0.001). Main histopathologic features of excised corneal buttons included corneal thinning and ulceration, loss of keratocytes, acute and chronic inflammation, stromal vascularization, and degenerative sequelae of long-standing inflammation. CONCLUSIONS: PKP in chronic or delayed-onset mustard gas keratitis should be considered as a high-risk graft; however, with appropriate management, graft clarity and visual outcomes may be favorable.
PURPOSE: To report the long-term outcomes of penetrating keratoplasty (PKP) in war victims with chronic and delayed mustard gas keratitis. METHODS: This noncomparative interventional case series includes patients with advanced chronic or delayed mustard gas keratitis who had undergone PKP from 1989 to 2006. Best-corrected visual acuity (BCVA), graft clarity, episodes of graft rejection, duration of steroid use, and complications were evaluated. Histopathologic features of excised corneal buttons were also evaluated. RESULTS: Overall, 22 eyes of 19 patients underwent PKP. Mean age at the time of surgery was 41 +/- 4.6 years (range, 36-54 years), and mean follow-up duration was 40.9 +/- 48 months (range, 4-204 months). The graft remained clear in 17 (77.3%) eyes and failed in 5 (22.7%) eyes. Overall, 13 (59.1%) eyes experienced episodes of endothelial rejection, and 5 (22.7%) eyes had subepithelial immune rejection, 4 of which had simultaneous endothelial rejection. Fifteen (68.2%) eyes received topical steroids for >6 months. Fourteen (63.6%) eyes developed cataracts, leading to cataract extraction in 7 eyes. One eye developed steroid-induced glaucoma after multiple episodes of endothelial graft rejections. Mean preoperative BCVA was 1.92 +/- 0.63 logMAR, which improved to 1.04 +/- 0.65 logMAR (20/200) overall and 0.8 +/- 0.3 logMAR (20/120) in eyes with clear grafts (P < 0.001). Main histopathologic features of excised corneal buttons included corneal thinning and ulceration, loss of keratocytes, acute and chronic inflammation, stromal vascularization, and degenerative sequelae of long-standing inflammation. CONCLUSIONS: PKP in chronic or delayed-onset mustard gas keratitis should be considered as a high-risk graft; however, with appropriate management, graft clarity and visual outcomes may be favorable.
Authors: Marion K Gordon; Andrea Desantis; Manjeet Deshmukh; Carl Jeffrey Lacey; Rita A Hahn; John Beloni; Sivanaga S Anumolu; John J Schlager; Michael A Gallo; Donald R Gerecke; Ned D Heindel; Kathy K H Svoboda; Michael C Babin; Patrick J Sinko Journal: J Ocul Pharmacol Ther Date: 2010-10 Impact factor: 2.671
Authors: Neera Tewari-Singh; Anil K Jain; Swetha Inturi; David A Ammar; Chapla Agarwal; Puneet Tyagi; Uday B Kompella; Robert W Enzenauer; J Mark Petrash; Rajesh Agarwal Journal: Toxicol Appl Pharmacol Date: 2012-07-24 Impact factor: 4.219
Authors: Neera Tewari-Singh; Claire R Croutch; Richard Tuttle; Dinesh G Goswami; Rama Kant; Eric Peters; Tara Culley; David A Ammar; Robert W Enzenauer; J Mark Petrash; Robert P Casillas; Rajesh Agarwal Journal: Cutan Ocul Toxicol Date: 2016-03-22 Impact factor: 1.820
Authors: Patrick M McNutt; Kaylie M Tuznik; Elliot J Glotfelty; Marian R Nelson; Megan E Lyman; Tracey A Hamilton Journal: Ann N Y Acad Sci Date: 2016-06-16 Impact factor: 5.691
Authors: David D Eveleth; Jennifer J Eveleth; Amuthakannan Subramaniam; Rita Hahn; Peihong Zhou; Marion K Gordon; Ralph A Bradshaw Journal: Invest Ophthalmol Vis Sci Date: 2018-09-04 Impact factor: 4.799